

Central Lancashire Online Knowledge (CLoK)

Title	Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of					
	Glycogen Synthase Kinase-3β					
Туре	Article					
URL	https://clok.uclan.ac.uk/id/eprint/36600/					
DOI	https://doi.org/10.1021/acs.jmedchem.0c01568					
Date	2021					
Citation	Davies, Matthew P, Benitez, Rocio, Perez, Concepcion, Jakupovic, Sven, Welsby, Philip John, Rzepecka, Klaudia Magdalena, Alder, Jane Elizabeth, Davidson, Colin, Martinez, Ana et al (2021) Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase- 3β. Journal of Medicinal Chemistry, 64 (3). pp. 1497-1509. ISSN 0022-2623					
Creators	Davies, Matthew P, Benitez, Rocio, Perez, Concepcion, Jakupovic, Sven, Welsby, Philip John, Rzepecka, Klaudia Magdalena, Alder, Jane Elizabeth, Davidson, Colin, Martinez, Ana and Hayes, Joseph					

It is advisable to refer to the publisher's version if you intend to cite from the work. https://doi.org/10.1021/acs.jmedchem.0c01568

For information about Research at UCLan please go to http://www.uclan.ac.uk/research/

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <u>http://clok.uclan.ac.uk/policies/</u>

Structure Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase – 3β

Matthew P. Davies,^a Rocio Benitez,^b Concepción Perez,^c Sven Jakupovic,^d Philip Welsby, ^a Klaudia Rzepecka,^a Jane Alder,^a Colin Davidson,^a Ana Martinez,^{*b,e} Joseph M. Hayes^{*a}

^a School of Pharmacy & Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, United Kingdom

^b Centro de Investigaciones Biologicas, CSIC, Avenida Ramiro de Maeztu 9,28040 Madrid, Spain

^c Instituto de Quimica Medica, CSIC, Juan de la Cierva 3, 28006 Madrid, Spain

^d AnalytiCon Discovery GmbH, Hermannswerder Haus 17, 14473 Potsdam, Germany

^e Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto Carlos III, 28031 Madrid, Spain.

Abstract: For the first time, the *in silico* design, screening and *in vitro* validation of potent GSK-3 β type-II inhibitors is presented. In the absence of crystallographic evidence for DFGout GSK-3 β activation loop conformation, computational models were designed using an adapted DOLPHIN approach and a method consisting of Prime loop refinement, induced-fit docking and molecular dynamics. Virtual screening of the Biogenics subset from the ZINC database led to an initial selection of 20 Phase I compounds revealing two low micromolar inhibitors in an isolated enzyme assay. 20 more analogues (Phase II compounds) related to the hit [pyrmidin-2-yl]amino–furo[3,2-*b*]furyl–urea scaffold were selected for structure activity relationship analysis. The Phase II studies lead to five highly potent nanomolar inhibitors, with compound **23** (IC₅₀=0.087 μ M) >100 times more potent than the best Phase I inhibitor, and selectivity for GSK-3 β inhibition compared to homologous kinases observed. *Ex-vivo* experiments (SH-SY5Y cell lines) for tau hyperphosphorylation revealed promising neuroprotective effects at low micromolar concentrations. Type-II inhibitor design has been unraveled as a potential route towards more clinically effective GSK-3 β inhibitors.

Keywords: Alzheimer's disease, DFG-out, kinase, loop prediction, type-II inhibitors

1. Introduction

Alzheimer's disease (AD) is a neurodegenerative disease and the most common form of dementia. Approximately 50 million people worldwide suffer from the condition.¹ However, current treatments do little more than partially alleviate some symptoms, or slow down the progression of the disease. According to the 'GSK-3 hypothesis of Alzheimer's disease', the increased activity and/or overexpression of the Ser/Thr kinase, Glycogen Synthase Kinase-3 β (GSK-3 β) is linked with both tau hyperphosphorylation and alterations in amyloid-beta processing, primers for formation of neurofibrillary tangles and senile plaques in AD, respectively.^{2, 3} Furthermore, GSK-3 β is highly expressed in the brain, is localized primarily in neurons,⁴ and its over-activity has been associated with neuronal loss.⁵ GSK-3 β inhibition, therefore, is viewed as an important target towards much needed new treatments and recent findings that GSK-3 β inhibitors ameliorate cognitive impairments caused by AD have led to a couple of candidates entering clinical trials.⁶⁻⁸ Importantly, GSK-3 β is also attracting considerable interest as a therapeutic target for a number of other conditions such as bipolar disorder, Parkinson's disease, epilepsy, cancer and type 2 diabetes.⁹⁻¹²

GSK-3 β is phylogenetically related to other kinases sharing the greatest homology with the cyclin dependent kinases (CDKs), protein kinase C (PKC) and mitogen activated protein kinases (MAPKs).¹³ Because of this homology, the design of potent and kinase selective type-I (ATP-binding site) inhibitors is challenging from a drug design perspective, with the highly conserved kinase Asp-Phe-Gly (DFG) motif of the activation loop orientated towards the binding site (DFG-in, active conformation). The design of ATP-binding site inhibitors of GSK-3 β has been extensively explored,^{14, 15} and researchers are now turning to other types of

inhibition so as to achieve inhibitors with better selectivity and efficacy. Some allosteric and substrate binding site inhibitors have been reported and reviewed.^{14, 15}

Design of inhibitors targeting the DFG-out inactive conformation (type-II inhibitors) has never been actively pursued for constitutively active GSK-3 β . However, the structural heterogeneity of the hydrophobic allosteric site immediately adjacent to the ATP-binding site, accessible in the "DFG-out" conformation means that type-II inhibitors have potential for greater selectivity.¹⁶⁻¹⁸ FDA approved clinical drugs such as imatinib (STI571) and sorafenib (BAY43-9006), that target other kinases, are type-II/DFG-out inhibitors. Kinase structural features necessary for DFG-out/type-II inhibition remain unclear, but the small L132 gatekeeper residue and the x = C199 residue of the xDFG motif in GSK-3 β are consistent with the viability of this mechanism.¹⁷⁻¹⁹ Studies have shown that C199 is a key residue in modulating GSK-3 β activity,^{20, 21} and covalent inhibition of GSK-3 β has just been reported exploiting C199 covalent interaction.²² Recently, evidence of the *Ustilago Maydis* fungal form of GSK-3 β undergoing type-II inhibition was reported.²³ Some of the compounds studied revealed less potent inhibition of the human isoform (Figure 1), but nevertheless indicating that type-II inhibition is possible.

In this study, we present *in silico* screening using Glide docking²⁴ of natural product based compounds against two different predicted DFG-out models of GSK-3β. The first structural model was generated used a DOLPHIN (Deletion Of Loop PHe-gly-IN) type approach,²⁵ which has previously reported successful applications.²⁶ The second DFG-out model was created using a combination of Prime loop prediction,^{27, 28} induced fit docking and then molecular dynamics for a final structural refinement. The two models were both used to screen a database of compounds taken from the Biogenics subset of the ZINC15 database.²⁹ An initial selection

of 20 predicted type-II inhibitors (Phase I compounds) from the *in silico* screening identified [pyrmidin-2-yl]amino – furo[3,2-*b*]furyl – ureas hit compounds following *in vitro* GSK-3 β binding assay experiments. This led to a focused structure activity relationship (SAR) analysis on an additional 20 analogues considering the hit scaffold (Phase II compounds). The best inhibitors (including five nanomolar potency compounds) were then tested *ex-vivo* for their neuroprotective effects at the cellular level, with promising neuroprotective effects observed at low micromolar concentrations. A typic inhibitor demonstrated favorable kinase selectivity against closely related homologous kinases.




Figure 1: Type-II inhibitor set of compounds consisting of sorafenib (1a - 1c) and BIRB–796 (1d - 1h) analogues previously tested against GSK-3 β . IC₅₀ inhibition data against both human and *Ustilago Maydis* (in parentheses) GSK-3 β are given.²³

2. Results & Discussion

2.1 Preliminary Computational Results

2.1.1 DOLPHIN Model Validation

The first DFG-out model of GSK-3 β was generated using an adapted DOLPHIN protocol,²⁵ and involved the deletion of the phenylalanine from the DFG loop, along with the next four residues. The deletion of the five residues opens up the space at the entrance to the allosteric site behind the DFG loop, allowing a type-II ligand to occupy both the hinge region of the ATP-binding site and the allosteric site. A key feature, therefore, of the DFG-out structure is the increased overall size of the binding site. Opening of the activation loop also positions the backbone of the aspartic acid of the DFG-in such a way that allows formation of the "classical" interactions of a type-II inhibitor: (a) one hydrogen bond with the DFG loop Asp, (b) one or two hydrogen bonds with the Glu from the α C helix and (c) an interaction with the hinge region. None of the classical type-II interactions will be affected by the five residue deletion, with Asp200, Glu97 and Val135 all still available for these hydrogen bond interactions.

The set of 8 ligands shown in Figure 1 were first used for validating the designed type-II models. This set consisted of two known type-II inhibitor scaffolds, sorafenib (3 analogues) and doramapimod/BIRB-796 (5 analogues) with inhibition data available for both human GSK-3 β inhibition, as well as the fungal *Ustilago Maydis* GSK-3 β isoform.²³ Results of the Glide-SP docking of these ligands to the DOLPHIN model were encouraging and revealed recognition of the active sorafenib analogues compared to the less-active BIRB-796 analogues in agreement with experiment (Table S1). Additionally, the sorafenib analogue relative potencies **1b** > **1c** > **1a** were correctly predicted. The predicted binding of sorafenib (**1a**) is shown in Figure 2 with the four classical interactions expected of a type-II inhibitor formed. Agreement with the known experimental data, along with the ligands' ability to form all of the classical interactions, led us to decide that the DOLPHIN model was suitable for type-II inhibitor virtual screening.




Figure 2: Predicted binding of sorafenib (**1a**) to GSK-3 β using the DOLPHIN model (left) compared to the DFG-out model from the Prime/molecular dynamics protocol (right). In both models, all of the classical type-II protein-ligand interactions are present and the now accessible allosteric site occupied. Protein-ligand hydrogen bonds are displayed as black dashed lines. PDB code 2OW3 was used as the initial starting model for calculations.

2.1.2 Prime/Molecular Dynamics Model Creation and Validation

Prime Loop refinement DFG-Out Structure

The second approach used to design a DFG-out model of GSK-3 β involved an initial Prime (activation) loop prediction.²⁸ The loop prediction was first trialed on *Ustilago Maydis* GSK-3 β (*Um*GSK-3 β) for which potent type-II inhibition compared to the human isoform was observed,²³ suggesting that the DFG-in to DFG-out transformation can be more easily achieved. In agreement, this calculation produced a DFG-out loop conformation with a

predicted relative energy of +4.5 kcal mol⁻¹ compared to the top ranked DFG-in conformation (Figure 3(A)).

However, the same calculation settings for human GSK-3β did not produce a DFG-out conformation. The strong contacts between Gln206 (next to the activation loop) with Lys103 (helix C) and Phe175 (helix E), the equivalent of which is not present in the $UmGSK-3\beta$ isoform (Figure 4), could inhibit the DFG-in to DFG-out transformation. This could also reflect, at least in part, the lower activities of the inhibitors **1a-1h** for human GSK-3β (Figure 1). The Prime loop prediction was repeated with Lys103 mutated to the equivalent residue type (isoleucine) present in UmGSK-3β. This K103I mutation successfully produced the DFG-out conformation (relative energy of +14.7 kcal/mol compared to DFG-in). The mutation was then reversed and the calculation repeated, producing the DFG-out structure shown in Figure 3(B) (relative energy of +13.3 kcal/mol compared to the top-ranked DFG-in structure). In this DFGout model, the Asp200 sidechain has been tucked away into the new shape of the flipped DFGout loop, and forms a number of hydrogen bonds with the loop backbone (Phe201 – Ala204). These interactions coupled with the new shape of the activation loop, which is very similar to that of $UmGSK-3\beta$ (Figure 3), opened the entrance to the allosteric site and creates space for type-II inhibitor binding. Induced fit docking (IFD)³⁰ has previously successfully been applied to predict protein-ligand contacts in agreement with experiment for other challenging cases,³¹⁻ ³³ and was used to further refine this new DFG-out model around a prototype type-II inhibitor, sorafenib (1a). Following the IFD, sorafenib formed all of the classical interactions that type-II ligands are expected to form, and the residues that line the entrance to the allosteric site have rearranged to better accommodate the ligand (Figure S1).




Figure 3: (**A**) The DFG-out activation loop conformation (Prime energy = -13441.3 kcal/mol) of *Ustilago Maydis* (*Um*)GSK-3 β obtained using Prime loop prediction compared to the DFG-in structure (-13445.8 kcal/mol). (**B**) In comparison, the DFG-out structure (-13514.4 kcal/mol) produced by Prime loop prediction of the wild-type human (*Hs*)GSK-3 β compared to the top scoring DFG-in structure from the same calculation (-13527.7 kcal/mol). The key Asp and Phe residues involved in the DFG-in to DFG-out transformation in both cases are highlighted. Shape similarity of the activation loops in (A) and (B) for the two isoforms is evident. PDB codes 4E7W (*Um* GSK-3 β) and 2OW3 (*Hs* GSK-3 β) were used as the initial starting models for calculations.




Figure 4: Hydrogen bonding in the human (*Hs*)GSK-3 β (green) DFG-in conformation involving residues Lys103, Gln206 and Phe175 that initially prevented the formation of the DFG-out conformation using Prime loop prediction. Similar strong contacts are absent for the *Ustilago Maydis* (*Um*)GSK-3 β isoform (brown). PDB codes 4E7W (*Um* GSK-3 β) and 2OW3 (*Hs* GSK-3 β) were used as the initial starting models for calculations.

Molecular Dynamics Simulation Results

To further refine and assess the stability of the generated DFG-out protein-ligand (**1a**) complex, a 20 ns MD simulation was performed using Desmond.²⁸ Equilibration of the system in terms of both backbone and sidechain root-mean-square deviations (RMSDs; Figure S2) was observed, and further analysis of protein-ligand interactions performed for the last 15 ns of the simulation.

As can be seen in Figure 2 (MD representative structure), all type-II inhibition classical interactions are present and were highly conserved (~90-98%) throughout the duration of the

simulation (Figures 5; Figure S3), indicative of the stability of the DFG-out loop conformation with bound sorafenib. Another noteworthy feature is the interactions with the gatekeeper residue, Leu132. Rather than hinder ligand binding, the small sidechain group of Leu132 forms favorable interactions with the sorafenib phenyl ring, observed ~50% of the MD duration.




Figure 5: Analysis of the interaction fraction of intermolecular interactions from molecular dynamics simulations of GSK-3 β DFG-out predicted complexes with (**A**) sorafenib and (**B**) most potent inhibitor from Phase II screening, compound **23**. For sorafenib, in terms of the classical type-II interactions, the two ligand urea NHs formed hydrogen bonds to the Glu97 sidechain for 0.93 and 0.95 of the simulation (total interaction fraction = 1.88); the urea O atom was hydrogen bonded with Asp200 backbone NH from the DFG loop for 0.98 of the time; and there was a highly conserved hydrogen bond (0.83) with the ATP-binding site hinge region residue Val135. The nature of hydrogen bond interactions were relatively similar for **23** (described in the text), but with Glu97 interactions water bridged (0.94 of simulation) and more favorable hydrophobic interactions, particularly with Ile62, Phe201 (including π – π stacking) and Tyr134 (*c.f.* also Figure S3).

Validation of Prime/Molecular Dynamics Model

Vijayan et al.¹⁸ performed a detailed analysis of kinase PDB entries, leading to proposals of two distances for 'classical' DFG-out conformations: $D_1 \le 7.2$ Å between the C α atoms of Asn in the HRDxxxxN motif and Phe in the DFG motif, and $D_2 \ge 9.0$ Å for the C α atom distance between the conserved Glu belonging to the α C-helix and Phe of the DFG motif. In near agreement, our model had values of 7.3 Å and 10.4 Å for D₁ and D₂, respectively.

The resultant model from Prime/Molecular Dynamics was additionally validated using known inhibition data for sorafenib and BIRB-796 analogues (Figure 1). The results of these Glide-SP docking calculations are shown in Table S1, and as with the DOLPHIN model, the predicted relative activity of the compounds is in good agreement with experiment. All sorafenib analogues were again correctly ranked higher than the BIRB-796 compounds (some bias towards sorafenib analogues is possible in this case based on the use of **1a** in the DFG-out model design), with each of the analogues predicted to have all classical type-II inhibition interactions. These results, similar to those from the DOPLHIN model, suggested the potential of the model for identification of novel type-II inhibitors.

2.1.3 Virtual Screening Results and Consensus scoring

Docking calculations of a filtered subset of the ZINC15 biogenic database²⁹ (27,286 ligands) using both GSK-3 β DFG-out models was performed and the predicted affinity ranks for both models combined using a KNIME workflow and the Simple Sum Rank consensus scoring method.³⁴ From the top 200 ranked compounds, 65 had GlideScores similar to the known active sorafenib analogues (\leq -9 for DOLPHIN model and \leq -10 for Prime/Molecular Dynamics model), and were chosen for further consideration. 20 candidates (**2-21**, Figure 6) from these top 65 were purchased for Phase I *in vitro* binding assay experiments, together with sorafenib as benchmark. The compounds were chosen with an emphasis on classical type-II interactions

first and then analysis of the additional interactions formed. The selection included diverse scaffolds consisting of [pyrmidin-2-yl]amino – furo[3,2-b]furyl – ureas, a cyclopentyl urea, a quinuclidine urea and pyrrolidine ureas; also included in this set were some 1-aralkylpyrrolidin-4-yl and 1-acyl-pyrrolidin-4-yl ethers. The consensus ranks of these 20 Phase I compounds, as well as their ranks and scores for each of the DFG-out models are included in the Table S2. None of the selected candidate inhibitors, Phase I or II, resulted in warnings for Pan Assay Interference Compounds (PAINS)³⁵ that often give false positive results in highdetermined using ZINC on-line filter throughput screens, as the (http://zinc15.docking.org/patterns/home/).




Figure 6: The structures of the 20 Phase I compounds (2-21) selected for *in vitro* GSK- 3β binding assay experiments, the results of which are shown in Table 1.

2.2 In Vitro GSK-3β Binding Assay Results

2.2.1 Phase I Compounds Binding Assay Results

The results of the *in vitro* binding assays against human GSK-3β for the initial Phase I 20

selected compounds (Figure 6) are summarized in Table 1. The percentage inhibition of GSK-

 3β at 50 μ M concentrations were first determined and for those compounds with > 50%

inhibition, IC₅₀ values were determined.

Table 1: Results of the *in vitro* GSK-3 β binding assay results obtained for Phase I (**2-21**, Figure 6) and Phase II (**22-41**, Figure 7) compounds. % inhibitions at 50 μ M concentrations are given where relevant. The IC₅₀ of the known type-II inhibitor sorafenib (**1a**, Figure 1) was determined as 32.64 ± 0.76 μ M and used as a benchmark for comparison.

Phase I Compounds				Phase II Compounds				
Compound	IC ₅₀ (μM)	Compound	IC ₅₀ (μM)	Compound	IC ₅₀ (μM)	Compound	IC ₅₀ (μM)	
2	26.96±1.77	12	> 50 µM (13%)	22	0.56±0.02	32	11.90±1.57	
3	9.75±2.2	13	> 50 µM (14%)	23	0.087±0.033	33	2.95±0.45	
4	> 50 µM (42%)	14	> 50 µM (5%)	24	0.412±0.030	34	2.70±0.15	
5	> 50 µM (7%)	15	> 50 µM (2%)	25	0.421±0.020	35	0.117±0.028	
6	> 50 µM (26%)	16	> 50 µM (2%)	26	2.06±0.20	36	1.08±0.17	
7	> 50 µM (1%)	17	> 50 µM (19%)	27	5.66±0.36	37	> 50 µM (21%)	
8	> 50 µM (1%)	18	> 50 µM (19%)	28	6.08±0.69	38	> 50 µM (35%)	
9	> 50 µM (5%)	19	> 50 µM (7%)	29	2.08±0.15	39	> 50 µM (21%)	
10	> 50 µM (6%)	20	> 50 µM (33%)	30	4.042±0.321	40	> 50 µM (41%)	

11	$> 50 \ \mu M$	21	$> 50 \ \mu M$	31	14.05 ± 1.85	41	$> 50 \ \mu M$
	(5%)		(14%)				(39%)

Compounds 2-21 resulted in a percentage inhibition of GSK-3 β ranging from ~1–90 % at 50 μ M concentration. Two low micromolar hit compounds 2 (IC₅₀ = 26.96 μ M) and 3 (IC₅₀ = 9.75 μ M) were identified, both [pyrmidin-2-yl]amino – furo[3,2-*b*]furyl – ureas, that had IC₅₀s better than the sorafenib benchmark compound (IC₅₀ = 32.64 μ M). The predicted binding modes of 2 and 3 were similar and are shown in Figure 7(A) and (B), respectively. All classical type-II inhibitor interactions are present. In the hinge region, there are hydrogen bonding interactions with both Val135 and Asp133 backbones. Structurally, the two ligands only differ in the positioning of a methoxy phenyl ring substituent, with a para-substitution favoured. In terms of the two GSK-3 β DFG-out models used in the *in silico* screening, the Prime/MD model ranked the more potent compounds higher (Table S2) and the Phase II compound selection was weighted accordingly.

2.2.2 Phase II Compounds Binding Assay Results

Based on the results of Phase I screening of compounds and the identification of the [pyrmidin-2-yl]amino – furo[3,2-*b*]furyl – ureas as a hit scaffold, it was decided to do a focussed SAR analysis on modifications of the hit structures. As a result, 20 further compounds (**22-41**) were selected for Phase II *in vitro* binding assay experiments, that included a range of different substitutions at different positions (Figure 8), including exploration of different furo[3,2*b*]furyl ring atom configurations for compounds **36-41**. The GlideScores and predicted rankings of these ligands in the original *in silico* screening are included in Table S3, the majority of which (17) were ranked in the top 500 compounds using the Prime/MD DFG-out model.




Figure 7: Predicted binding interactions from Glide-SP docking to the Prime/MD representative GSK-3 β model of the most potent inhibitors from the Phase I compounds (A) **2** (IC₅₀ = 26.96 μ M) and (B) **3** (IC₅₀ = 9.75 μ M), as well as the representative protein-ligand structure from MD simulations of the most potent nanomolar inhibitor from Phase II compounds, (C) **23** (IC₅₀ = 0.087 μ M). For compounds **23**, the interactions in the allosteric pocket of the DFG-out conformation are also separately highlighted, with the phenyl CN substituent of **23** buried between three hydrophobic sidechains of residues Ile109, Ile172 and

Leu198. Protein-ligand hydrogen bonds are displayed as black dashed lines. PDB code 2OW3 was used as the initial starting model for calculations.

The results of the Phase II GSK-3β binding assay experiments are displayed in Table 1. These new experiments revealed a number of very potent inhibitors, the best compound > 100 times more potent than its Phase I equivalent (3). Five of the compounds (22-25 and 35) were in the nanomolar range, with eight new low micromolar inhibitors identified. The most potent compounds were 23 (IC₅₀ = 0.087 μ M) and 35 (IC₅₀ = 0.117 μ M). A 100 ns MD simulation was used to further explore the binding of the most potent inhibitor 23 (c.f. also .mp4, Supporting Information). Similar protein-ligand interactions to those observed in the preliminary docking screening (Figure S4) were observed, with a MD representative model shown in Figure 7(C); the interaction fractions from the simulation are shown in Figure 5(B). There are strong direct hydrogen bond contacts (100% duration) with Asp200 backbone NH from the DFG-out loop; hinge region hydrogen bonds involving inhibitor 2-aminopyrimidine group with Asp133 (44.2% duration) and Val135 (14.3% duration). Compared to sorafenib (Figure 5(A)), there are more favorable hydrophobic contacts interactions in the allosteric hydrophobic pocket (Met101; Leu104) and through interactions with the *p*-methoxy-phenyl group (Ile62; Phe201) (c.f. also Figure S3). The inhibitor methoxy O atom is also involved in hydrogen bond interaction, direct (9.3% duration) or water-bridged (18.2% duration), with Asn64. The key difference in the MD representative compared to docking prediction (and sorafenib binding) is that interactions with Glu97 are predicted to be predominantly water bridged as opposed to direct, but are almost present throughout (94.0% duration). As this is a model, it is still possible that these hydrogen bonds may in fact be direct, as predicted from docking (Figure S4).

Using **3** (IC₅₀ = 9.75 μ M) as a basis for SAR analysis (Figure 8), we first investigated substitutions at different positions of both terminal phenyl rings (<u>1</u> and <u>2</u>) through compounds

22–29. Keeping the –OMe (para) on phenyl <u>1</u> fixed as in compound **3** and exploring X_2 substitutions (phenyl <u>2</u>) revealed four nanomolar inhibitors, **22** with $X_2 = H$ (IC₅₀ = 0.560 µM), **24** with $X_2 = C(O)Me$ (para) (IC₅₀ = 0.412 µM), **23** with $X_2 = CN$ (meta) (IC₅₀ = 0.087 µM) and **25** with $X_2 = OMe(3,5)$ (IC₅₀ = 0.421 µM). Hence, a –CN (meta) substitution was particularly effective (Figure 7(C)).

With either $X_2 = CF_3$ (meta) or CN (meta) and instead exploring X_1 substitutions (phenyl <u>1</u>) resulted in less potent but still low micromolar inhibitors (**26–29**), highlighting the importance of the $X_1 = OMe$ (para) substituent of the nanomolar compounds which formed the aforementioned hydrogen bond interactions with Asn64 in the MD simulation for compound **23** (Figures 5(B) and S3). Additionally, having an ethyl group (**35**, IC₅₀ = 0.117 µM) instead of the phenyl <u>2</u> group also revealed nanomolar potency; predicted binding from Prime/MD representative model docking is shown in Figure S4.

Compounds **30**, **32** and **33** investigated replacements of the phenyl <u>1</u> substituent of the pyrimidine of **3** with different five membered rings (X₁ substitutions), and **31**, replacement with an isopropyl group. This had a modest effect on potency with all compounds demonstrating low micromolar potency, the best of which (**33**, furan ring substituent) had an IC₅₀ of 2.95 μ M. Replacing the X₂ = CF₃ group of **30** (IC₅₀ = 4.04 μ M) with a hydrogen (**34**; IC₅₀ = 2.70 μ M) had little effect on potency.




Figure 8: Phase II selection of compounds (**22-41**) for *in vitro* GSK-3β binding assay experiments. The most potent inhibitor (**3**) from Phase I is highlighted as a basis for SAR analysis

Substitution of the urea group (red, Figure 7) of **3** with a –NHC(O)O– linker together with a change of configuration in the furo[3,2-*b*]furyl ring for **36** led to reduced hydrogen bond contact to Glu97 from docking predictions but together with the effects of fusing the phenyl at ring position <u>1</u> with a 1,3-dioxolane still resulted in low micromolar inhibition (IC₅₀ = 1.08 μ M). Significantly, replacement of the 2-aminopyrimidine substituent of **3** (blue, Figure 7) with other entities and different configurations of the furo[3,2-*b*]furyl ring (compounds **37–41**) all led to loss of hinge region interactions and resulting poor inhibition (IC₅₀ > 50 μ M).

2.3 Kinase Selectivity Screen

To probe the potential selectivity of the new potent compounds for GSK-3 β inhibition, selectivity screening of the nanomolar inhibitors **23** and **24** against eleven other kinases (CDK2, CDK5, CDK9, ERK1, ERK2, PKA, PKB α , PKB β , PKC α , PKC γ and GSK-3 α) was performed with the results shown in Figure 9. The results of this single dose profiling (5 μ M) revealed significantly selectivity towards GSK-3 β inhibition over the other enzymes. The most potent GSK-3 β inhibitor **23** was highly selective for GSK-3 β compared to the other kinases, and also demonstrated slight selectivity for GSK-3 β inhibition over its GSK-3 α isoform. Compound **24**, which demonstrated a better profile in the cell viability experiments (*vide infra*), had better selectivity for GSK-3 β over GSK-3 α ; all other enzymes had > 50% remaining activity with the exception of CDK9 (33.8%). CDK9 plays a key role in inflammation, with neuroinflammation a hallmark of neurological disorders. Moreover, dual GSK-3 β /CDK9 inhibitors have shown interesting antinflammatory and anticancer profile both *in vitro* and *in vivo*.³⁶




Figure 9: Single dose (5 μ M) selectivity profile of GSK-3 β nanomolar inhibitors **23** and **24** versus eleven homologous kinases shown as the % remaining activity \pm standard deviation.

2.4 Ex-vivo Experiments – Tau Hyperphosphorylation

Nanomolar (22-25 and 35) along with four low micromolar (26, 28, 29 and 36) inhibitors from Phase II screening progressed to *ex-vivo* experiments. The okadaic acid (OA)-induced neurodegeneration cell model was used to explore the anti-tau profile of the GSK-3 β inhibitors in comparison with the well known GSK-3 β inhibitor TDZD-8,³⁷ structurally similar to previous AD clinical trials candidate, tideglusib.³⁸ OA-treated cell lines and primary neuronal cultures have been used as established cellular models of hyperphosphorylated tau-induced neurodegeneration.^{39, 40} The phosphorylation of tau by GSK-3 β and its relation to formation of neurofibrillary tangles has been well documented ⁴¹⁻⁴³ and the reduction of phosphorylated tau by GSK-3 β inhibition demonstrated,^{44, 45} and so neuroprotective effects of the compounds in the experiments can be most likely mainly attributed to their potent inhibition of GSK-3 β .

We studied the effects of the chosen compounds at five different concentrations (Figure 10). As expected, OA induced a decrease in cell viability of more than 50%. These data show that the test compounds all inhibit the toxic effects of okadaic acid except compounds **28** (Fig. 10-**G**) and **36** (Fig. 10-**J**). Of the active compounds, they were all protective at lower concentrations than our benchmark compound TDZD-8, with all test compounds (except **28** and **36**) active at the lowest concentration tested (0.1 μ M). Compound **24** (Fig. 10-**D**), **26** (Fig. 10-**F**), **29** (Fig. 10-**H**) and **35** (Fig. 10-**I**) appear to have the best profile, being active at the 3 lowest concentrations. The GSK-3 β inhibitory potencies cannot be accurately correlated with the functional effects seen in Figure 10. This could at least in part be attributed to the relative similarities of the GSK-3 β inhibitor potencies together with potential differences in their pharmacokinetic properties.




Figure 10: Effects of identified GSK-3 β inhibitors **22-26**, **28-29** and **35-36** on an okadaic acid-induced neurodegeneration cell model. The efficacy of five different inhibitor concentrations were tested (0.1, 0.5, 1, 5 and 10 μ M), with TDZD-8 used as a benchmark inhibitor for comparison. Okadaic acid caused a significant reduction in cell viability (to 43.08% of control values, T(194) = 14.98, P < 0.0001; data not shown). The data presented in the graph are cell viability as a percentage of control. In all cases okadaic acid is present at 30 μ M. Data are the mean ± SEM of three independent experiments at each test compound concentration. Cell line: SH-SY5Y. Data in each panel A-J were analysed using a 1-way ANOVA with post hoc analysis with Bonferonni test versus okadaic acid. *p < 0.05; **p < 0.01; ***p < 0.001 significant difference versus okadaic acid alone. Nsd = no significant difference.

3. Conclusions

GSK-3ß is an important target for the development of much needed new treatments for CNS disorders such as AD. We have explored, for the first time, the design of ligands to stablize the DFG-out conformation of the enzyme in a type-II inhibition mechanism. For this purpose, two different type-II DFG-out models (DOLPHIN and Prime/MD) were used for Glide-SP virtual screening of 27,286 natural product derivatives. Candidates from this were selected for in vitro GSK-36 binding assay experiments in two phases, Phase I and II. Phase I results revealed two low micromolar inhibitors, 2 (IC₅₀ = 27 μ M) and 3 (IC₅₀ = 9.8 μ M), both of which had a [pyrmidin-2-yl]amino – furo[3,2-b]furyl – urea scaffold. Selection of 20 more analogues based on this scaffold for Phase II experiments revealed 5 highly potent inhibitors (22-25 and 35) on the nanomolar range and 8 additional low micromolar inhibitors. Compared to the DOLPHIN structure, the Prime/MD DFG-out model generally ranked the potent inhibitors higher, highlighting the potential of the model for identification of other hit compounds with different chemical scaffolds using virtual screening. Kinase selectivity profiling for compounds 23 and 24 against eleven homologous kinases revealed good selectivity for GSK-3β inhibition. Additionally, some of the most potent inhibitors demonstrated neuroprotective effects in a OAinduced neurodegeneration cell-based model with efficacy greater than that of the standard reference TDZD-8 at low micromolar concentrations. [Pyrmidin-2-yl]amino – furo[3,2-b]furyl - ureas have therefore been identified as a privileged scaffold for development of GSK-3 β , and potentially other kinase type-II inhibitors. This study has also unravelled the unexplored potential for the design of more effective GSK-3ß inhibitors (selective, longer duration of action) targeting a type-II mechanism.^{46,47} The potential for type-II inhibition with other kinases may be performed in a similar manner, given that the type-II inhibition phenomenon might extend to a wide range of kinases.

4. Experimental

4.1 Computational Methods

4.1.1 Ligand Preparation

All ligands were prepared for docking using Maestro and LigPrep v3.6 at a pH of 7.0 +/- 1.0. The Biogenics subset from the ZINC15 database²⁹ was downloaded for the virtual screening, with the purchasable filter applied. ADMET predicted properties from QikProp 4.6²⁸ in standard mode were used to filter the compounds based on a previous property analysis of 30 diverse ATP-binding site (type-I) GSK-3 β inhibitors from clustering of nanomolar potency compounds (M.P. Davies, *unpublished*): 200 ≤ MW ≤ 650 Da, 0 ≤ LogP o/w ≤ 5, Hydrogen Bond Acceptors (HBAs) ≤ 11, Hydrogen Bond Donors (HBDs) ≤ 6. Too much flexibility hinders permeability, so that number of rotatable bonds ≤ 10 based on Veber's rules was applied.⁴⁸ The final screening set consisted of 27,286 ligands, or 45,092 including the different tautomers and ionisation states.

4.1.2 Protein Preparation (DFG-in)

The initial preparation of GSK-3 β for calculations was performed using Schrödinger's Protein Preparation Wizard²⁸ and the protein from PDB code: 2OW3 (2.8 Å resolution)⁴⁹. 2OW3 was chosen due to its more open binding site bound to a bis-(indole) maleimide pyridinophane inhibitor and previous successes in type I inhibitor screening;⁵⁰ the more open binding site was also determined as more suitable in initial trials for generating DFG-out models (compared to PDB code: 1H8F). Water molecules within 5 Å of the ligand were initially retained but deleted for subsequent calculations. Bond orders were assigned and hydrogen atoms added, with protonation states for basic/acidic residues based on calculated residue *pKa* values from PROPKA⁵¹ at normal pH (7.0). Subsequent optimization of hydroxyl groups, histidine protonation states and C/N atom "flips", and side-chain O/N atom flips of Asn and Gln residues was based on optimizing hydrogen bonding patterns. Finally, an Impref minimization of the GPb complex was performed using the OPLS3 forcefield⁵² to remove any steric clashes and bad contacts. At the end of the minimization, the RMSD of all heavy atoms was within 0.3 Å of the crystallographic positions. The preparation of *Ustilago Maydis* GSK-3 β (PDB code 4E7W; 3.3 Å resolution)²³ and was performed in a similar manner.

4.1.3 DOLPHIN Docking Details

For creation of the DOLPHIN GSK-3 β model, the phenylalanine of the DFG loop (Phe201) was selected and deleted, along with the next 4 residues (202-205). The use of a similar original yielded consistent approach in the paper results with the full DOLPHIN/pharmacophore field approach.²⁵ An initial Glide 7.2²⁸ grid (29.5 Å \times 29.5 Å \times 29.5 Å) for positioning of the type-II ligand sorafenib (1a) into the site was achieved using the center of hinge region residues Asp133-Val135 and DFG loop Asp200. Using the docked model of **1a**, a new docking grid was calculated centred on **1a** and used for the validation of the model and the subsequent virtual screening. Glide in SP mode was used for all docking calculations and incorporated post-docking minimization with strain correction. Standard parameters were otherwise applied, including default OPLS3 atomic charges and van der Waals scaling (0.8) for ligand nonpolar atoms to include modest 'induced fit' effects.

4.1.4 Prime/Molecular Dynamics Model

Activation Loop Refinement

The prepared DFG-in GSK-3 β structure (4.1.2) was used in Prime 4.5 loop refinement calculations²⁸ in attempts to generate a DFG-out model. To achieve this, the calculations were performed on wild-type GSK-3 β and a K103I mutated form, as outlined in the results. The calculation settings incorporated use of VSGB implicit solvation⁵³ which is based on the Surface Generalized Born (SGB) model and the variable dielectric (VD) treatment of polarization from protein sidechains, the OPLS3 forcefield⁵² and with the activaton loop residues 199-204 selected for refinement.

IFD calculations²⁸ of sorafenib (**1a**) to the DFG-out model generated from the Prime loop refinement was performed. The docking grid of dimensions 29.5 Å × 29.5 Å × 29.5 Å was centred on the sorafenib pose from the DOLPHIN calculations, superimposed into the site. IFD calculations consisted of three stages. In Stage I, initial Glide 7.2 SP docking^{24, 28} was performed, with a maximum of 20 poses saved. To increase the size of the binding pocket, two residues (Met101 and Asp200) were selected for mutation to Ala during this initial docking (rebuilt in Stage II). In Stage II, protein residues within 7 Å of the initial protein-ligand poses were refined using Prime 4.5.^{27, 28} Finally in Stage III, up to 20 structures from Stage II within 30 kcal/mol of the lowest energy structure were used for Glide-SP ligand re-docking calculations. The final protein-ligand geometries were analyzed in terms of structure and binding interactions, as well as the IFDScores (re-docking Glidescore + 5% Prime energy).

MD refinement

The top scoring GSK-3 β -sorafenib complex structure from the IFD calculations was used as input for MD using Desmond v3.6.²⁸ The initial set-up for simulation involved soaking the system with a pre-equilibrated TIP3P model orthorhombic water box check the sides lengths (sides a = 83.98 Å, b = 87.25 Å, c = 72.34 Å; volume 530,034 Å³), allowing a 10 Å buffer region between protein and box sides, and neutralizing the system with six Cl⁻ ions. This setup procedure produced 15,064 water molecules with the final system consisting of 50,907 atoms. Heavy atom bond lengths with hydrogens and the internal geometry of water molecules were constrained using the SHAKE algorithm. Atom types and forcefield parameters from OPLS3⁵² were assigned to the system. Periodic boundary conditions (PBC) were applied and a cut-off of 9.0 Å for non-bond interactions, with electrostatic interactions treated using the Particle Mesh Ewald (PME) method.⁵⁴ The default standard Desmond relaxation and equilibration protocol was employed, followed by a 20 ns production run in the NPT ensemble (T = 300 K, thermostat

relaxation time = 1.0 ps; P = 1 atm, barostat relaxation time = 2.0 ps) using a Nose-Hoover thermostat and Martyna-Tobias-Klein barostat.^{55, 56} A multiple timestep RESPA integration algorithm was used with timesteps of 2, 2, and 6 fs for bonded, "near" nonbonded, and "far" nonbonded interactions, respectively. Energy and trajectory atomic coordinate data were collected every 1.2 and 5.0 ps, respectively. Visualization and analysis of the MD trajectory was performed employing Desmond Maestro's simulation analysis tools. Employing Maestro's Desmond trajectory clustering tool and the hierarchical cluster linkage method, clustering of 4000 trajectory frames from the last 15 ns (ligand and protein residues within 7 Å)⁵⁷ into 10 clusters based on atomic RMSDs was performed and a representative structure taken from the most populated cluster to be used as the final DFG-out model.

Docking Details

For the docking calculations, the representative structure from the MD was used and the same settings as those described in 4.1.3 for DOLPHIN docking were applied, with the docking grid (29.5 Å \times 29.5 Å \times 29.5 Å) centred on the bound sorafenib (**1a**) ligand.

4.1.5 Molecular Dynamics GSK-3β – Compound 23 Complex

The predicted GSK-3 β DFG-out complex with compound **23** from docking to the Prime/MD model was used as input for MD simulation using Desmond v3.6. System set-up details were as indicated for the corresponding Prime/MD simulation but in this case the orthorhombic box having dimensions a = 90.94 Å, b = 71.05 Å, c = 79.42 Å (volume 513,164 Å³), including 14,444 water molecules and the final systems consisting of 49,058 atoms. The relaxation protocol was as previously described, as was the production run except in this case an extended 100 ns MD simulation was performed. Desmond trajectory clustering was again used to obtain a representative model of the protein – ligand complex: frames from the last 60 ns of the simulation (ligand and protein residues within 7 Å) were clustered into 10 groups and the representative structure from the largest cluster taken.

4.2.1 In Vitro GSK-3β Binding Assays

All predicted inhibitors for testing were from Analyticon Discovery, Germany. The purity data is included in the Supporting Information. Purity of all screening compounds was at least 85% based on ¹H-NMR and HPLC by absorbance at 215 nm wavelength. The purity of all nanomolar inhibitors 22-25 and 35 was 100%, as determined using HPLC-MS-DAD and ¹H-NMR. Highperformance liquid chromatography equipped with single quadrupol mass spectrometry, diode array and evaporative light scattering detectors (HPLC-MS-PDA-ELSD) was carried out on Shimadzu LC-20 AD XR using Gemini-NX C18 3µM, 3 mm×50 mm reverse phase column, eluted with a 6 min gradient system of 5:95 to 100:0 methanol:water, consisting a buffer of 5mM ammonium bicarbonate adjusted to pH 10.4 with ammonia, at a flow rate of 1.2 ml/min. Mass spectra (MS) were performed using positive and negative electrospray ionization (ESI). NMR spectra were measured on a Bruker 500 MHz NMR instrument. Sorafenib was purchased from Key Organics U.K. Human recombinant GSK-3ß and the pre-phosphorylated polypeptide substrate were purchased from Millipore (Millipore Iberica SAU). Kinase-Glo Luminescent Kinase Assay was obtained from Promega (Promega Biotech Iberica, SL). ATP and all other reagents were from Sigma Aldrich (St. Louis, MO). Assay buffer contained 50 mM HEPES (pH 7.5), 1 mM EDTA, 1 mM EGTA, and 15 mM magnesium acetate. The method of Baki et al. was followed to analyse the inhibition of GSK-3⁶, ⁵⁸ Kinase-Glo assays were performed in assay buffer using black 96-well plates. In a typical assay, 10 µL (10 µM) of test compound (dissolved in dimethyl sulfoxide [DMSO] at 1 mM concentration and diluted in advance in assay buffer to the desired concentration) and 10 µL (20 ng) of enzyme were added to each well followed by 20 µL of assay buffer containing 25 µM substrate and 1 µM ATP. The final DMSO concentration in the reaction mixture did not exceed 1%. After 30 min incubation at 30 °C, the enzymatic reaction was stopped with 40 µL of KinaseGlo reagent. Glow-type luminescence was recorded after 10 min using a FLUOstar Optima (BMG Labtechnologies GmbH, Offenburg, Germany) multimode reader. The activity is proportional to the difference of the total and consumed ATP. The inhibitory activities were calculated based on maximal activities measured in the absence of inhibitor. The IC_{50} was defined as the concentration of each compound that reduces a 50% the enzymatic activity with respect to that without inhibitors.

4.2.2 Kinase Selectivity Screening

Selected compounds were assayed in duplicate at a single concentration (5 μ M) against CDK2, CDK5, CDK9, ERK1, ERK2, PKA, PKB α , PKB β , PKC α , PKC γ , GSK-3 α and GSK-3 β using a specialist service from the MRC-Protein Phosphorylation & Ubiquitylation Unit at the University of Dundee (http://www.kinase-screen.mrc.ac.uk/).

4.2.3 Ex Vivo Tau Hyperphosphorylation Assays

The okadaic acid-induced tau hyperphosphorylation cell model was run in human neuroblastoma cell line SH-SY5Y. Cells were grown in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin at 37 0 C and 5% CO₂ in an incubator. SH-SY5Y cells were seeded onto a 96-well plate at 60.000 cells per well. 48 h later, cells were pre-incubated with the compounds at the desired concentration for 1 h and after that time okadaic acid (OA) (Sigma Aldrich, catalogue no: 09381) was added at a concentration of 30 nM and incubated for another 24 h. Afterwards, cells were incubated with 0.5 mg mL⁻¹ MTT solution for at least 4 h at 37 0 C and 5% CO₂. Then culture media was removed and the formazan crystals attached to the bottom of the plate were dissolved with 200 mL of DMSO. Finally, UV-absorbance was measured at 595 nM in a microplate reader (Varioskan Flash Microplate reader, Thermo Scientific).

Supporting Information

The Supporting Information is available free of charge. Predicted potency rankings of the Phase I and II compounds from the virtual screening; Supplementary Figures from calculations; ¹H NMR and ¹³C NMR characterization data for the nanomolar inhibitors (**22-25** and **35**); copies

of ¹H-NMR and MS spectra as well as HPLC-chromatograms; molecular strings formula (SMILES) and % purities of tested compounds (CSV).

Corresponding Authors

* Joseph M. Hayes; email: jhayes@uclan.ac.uk

* Ana Martinez; e-mail: <u>ana.martinez@csic.es</u>

Abbreviations Used

AD, Alzheimer's disease; ADMET, absorption, distribution, metabolism, excretion, and toxicity; ATP, adenosine 5'-triphosphate; CDK, cyclin-dependent kinase; DAD, diode-array Dulbecco's nodified eagle medium; DMSO, dimethyl sulfoxide; detection; DMEM, DOLPHIN, Deletion Of Loop PHe-gly-IN; EDTA, ethylenediaminetetraacetic acid; EGTA, ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid; ELSD, evaporative light scattering detector; ERK, extracellular signal-regulated kinase; FBS, fetal bovine serum; GSK, glycogen synthase kinase; HPLC, high-performance liquid chromatography; IC₅₀, halfmaximum inhibitory concentration; IFD, induced fit docking; KNIME, Konstanz information miner; LogP, logarithm of partition coefficient; MD, molecular dynamics; MS, mass spectrometry; MTT, methylthiazolyldiphenyl-tetrazolium bromide; NMR, nuclear magnetic resonance; OA, okadaic acid; PBC, periodic boundary conditions; PDA, photodiode arrav: PDB, Protein Data Bank; PKA, protein kinase A; PKB, protein kinase B; PKC, protein kinase C; PME, particle mesh Ewald; RESPA, reversible reference system propagator algorithm; RMSD, root mean square deviation; SAR, structure-activity relationship; SGB, surface generalized Born

References

1. World Health Organisation, <u>www.who.int</u> (accessed Sep 1, 2020).

2. Hooper, C.; Killick, R.; Lovestone, S., The GSK3 hypothesis of Alzheimer's disease. *J Neurochem* **2008**, *104* (6), 1433-1439.

3. Hernandez, F.; Lucas, J. J.; Avila, J., GSK3 and tau: Two convergence points in Alzheimer's disease. *J Alzheimers Dis* **2013**, *33*, S141-S144.

4. Takahashi, M.; Tomizawa, K.; Kato, R.; Sato, K.; Uchida, T.; Fujita, S. C.; Imahori, K., Localization and developmental-changes of tau-protein kinase I/glycogen synthase kinase-3-beta in rat-brain. *J Neurochem* **1994**, *63* (1), 245-255.

5. Martinez, A.; Perez, D. I., GSK-3 inhibitors: A ray of hope for the treatment of Alzheimer's disease? *J Alzheimers Dis* **2008**, *15* (2), 181-191.

6. Martinez, A.; Perez, D. I.; Gil, C., Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease. *Curr Top Med Chem* **2013**, *13* (15), 1808-1819.

7. Eldar-Finkelman, H.; Martinez, A., GSK-3 inhibitors: Preclinical and clinical focus on CNS. *Front Mol Neurosci* **2011**, *4*, 32.

8. King, M. K.; Pardo, M.; Cheng, Y. Y.; Downey, K.; Jope, R. S.; Beurel, E., Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. *Pharmacol Therapeut* **2014**, *141* (1), 1-12.

9. Cohen, P.; Goedert, M., GSK3 inhibitors: Development and therapeutic potential. *Nature Reviews Drug Discovery* **2004**, *3* (6), 479-487.

 Aourz, N.; Serruys, A. K.; Chabwine, J. N.; Balegamire, P. B.; Afrikanova, T.; Edrada-Ebel, R.; Grey, A. I.; Kamuhabwa, A. R.; Walrave, L.; Esguerra, C. V.; van Leuven, F.; de Witte, P. A. M.; Smolders, I.; Crawford, A. D., Identification of GSK-3 as a potential therapeutic entry point for epilepsy. *ACS Chem Neurosci* 2019, *10* (4) 1992–2003.
 Morales-Garcia, J. A.; Susin, C.; Alonso-Gil, S.; Perez, D. I.; Palomo, V.; Perez, C.; Conde, S.; Santos, A.; Gil, C.; Martinez, A.; Perez-Castillo, A., Glycogen synthase

kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chemical Neuroscience **2013**, *4* (2), 350-360.

12. Zhou, A. D.; Lin, K. Y.; Zhang, S. C.; Chen, Y. H.; Zhang, N.; Xue, J. F.; Wang, Z. Y.; Aldape, K. D.; Xie, K. P.; Woodgett, J. R.; Huang, S. Y., Nuclear GSK3 beta promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. *Nat Cell Biol* **2016**, *18* (9), 954-966.

13. Meyerson, M.; Enders, G. H.; Wu, C. L.; Su, L. K.; Gorka, C.; Nelson, C.; Harlow, E.; Tsai, L. H., A family of human Cdc2-related protein-kinases. *EMBO J* **1992**, *11* (8), 2909-2917.

14. Arfeen, M.; Bharatam, P. V., Design of glycogen synthase kinase-3 inhibitors: An overview on recent advancements. *Curr Pharm Design* **2013**, *19* (26), 4755-4775.

15. Pandey, M. K.; DeGrado, T. R., Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging. *Theranostics* **2016**, *6* (4), 571-593.

16. Liu, Y.; Gray, N. S., Rational design of inhibitors that bind to inactive kinase conformations. *Nat Chem Biol* **2006**, *2* (7), 358-364.

17. Treiber, D. K.; Shah, N. P., Ins and outs of kinase DFG motifs. *Chem Biol* **2013**, *20* (6), 745-746.

18. Vijayan, R. S. K.; He, P.; Modi, V.; Duong-Ly, K. C.; Ma, H. C.; Peterson, J. R.; Dunbrack, R. L.; Levy, R. M., Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors. *J Med Chem* **2015**, *58* (1), 466-479.

19. Hari, S. B.; Merritt, E. A.; Maly, D. J., Sequence determinants of a specific inactive protein kinase conformation. *Chem Biol* **2013**, *20* (6), 806-815.

20. Perez, D. I.; Conde, S.; Perez, C.; Gil, C.; Simon, D.; Wandosell, F.; Moreno, F. J.; Gelpi, J. L.; Luque, F. J.; Martinez, A., Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. *Bioorgan Med Chem* **2009**, *17* (19), 6914-6925.

21. Perez, D. I.; Palomo, V.; Perez, C.; Gil, C.; Dans, P. D.; Luque, F. J.; Conde, S.; Martinez, A., Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: Clues for specific design of new compounds. *J Med Chem* **2011**, *54* (12), 4042-4056.

22. Redenti, S.; Marcovich, I.; De Vita, T.; Perez, C.; De Zorzi, R.; Demitri, N.; Perez, D. I.; Bottegoni, G.; Bisignano, P.; Bissaro, M.; Moro, S.; Martinez, A.; Storici, P.; Spalluto, G.; Cavalli, A.; Federico, S., A triazolotriazine-based dual GSK-3 beta/CK-1 delta ligand as a potential neuroprotective agent presenting two different mechanisms of enzymatic inhibition. *ChemMedChem* **2019**, *14* (3), 310-314.

23. Grutter, C.; Simard, J. R.; Mayer-Wrangowski, S. C.; Schreier, P. H.; Perez-Martin, J.; Richters, A.; Getlik, M.; Gutbrod, O.; Braun, C. A.; Beck, M. E.; Rauh, D., Targeting GSK3 from *Ustilago maydis*: Type-II kinase inhibitors as potential antifungals. *ACS Chem Biol* **2012**, *7* (7), 1257-1267.

24. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S., Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *J Med Chem* **2004**, *47* (7), 1739-1749.

25. Kufareva, I.; Abagyan, R., Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. *J Med Chem* **2008**, *51* (24), 7921-7932.

26. Ma, D. L.; Chan, D. S. H.; Wei, G.; Zhong, H. J.; Yang, H.; Leung, L. T.; Gullen, E. A.; Chiu, P.; Cheng, Y. C.; Leung, C. H., Virtual screening and optimization of Type II inhibitors of JAK2 from a natural product library. *Chem Commun* **2014**, *50* (90), 13885-13888.

27. Jacobson, M. P.; Pincus, D. L.; Rapp, C. S.; Day, T. J. F.; Honig, B.; Shaw, D. E.; Friesner, R. A., A hierarchical approach to all-atom protein loop prediction. *Proteins* **2004**, *55* (2), 351-367.

28. Schrödinger Release 2016-3, Schrödinger, LLC, New York, NY, 2016.

29. Sterling, T.; Irwin, J. J., ZINC 15-ligand discovery for everyone. *J Chem Inf Model* **2015**, *55* (11), 2324-2337.

30. Sherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R., Novel procedure for modeling ligand/receptor induced fit effects. *J Med Chem* **2006**, *49* (2), 534-553.

31. Chatzileontiadou, D. S. M.; Tsika, A. C.; Diamantopoulou, Z.; Delbe, J.; Badet, J.; Courty, J.; Skamnaki, V. T.; Parmenopoulou, V.; Komiotis, D.; Hayes, J. M.; Spyroulias, G. A.; Leonidas, D. D., Evidence for novel action at the cell-binding site of human angiogenin revealed by heteronuclear NMR spectroscopy, *in silico* and *in vivo* studies. *ChemMedChem* **2018**, *13* (3), 259-269.

32. Wu, G. S.; Vashishtha, S. C.; Erve, J. C. L., Characterization of glutathione conjugates of duloxetine by mass spectrometry and evaluation of *in silico* approaches to rationalize the site of conjugation for thiophene containing drugs. *Chem Res Toxicol* **2010**, *23* (8), 1393-1404.

33. Georgatza, D.; Gorgogietas, V. A.; Kylindri, P.; Charalambous, M. C.; Papadopoulou, K. K.; Hayes, J. M.; Psarra, A. M. G., The triterpene echinocystic acid and its 3-O-glucoside derivative are revealed as potent and selective glucocorticoid receptor agonists. *Int J Biochem Cell B* **2016**, *79*, 277-287.

34. Feher, M., Consensus scoring for protein-ligand interactions. *Drug Discov Today* **2006**, *11* (9-10), 421-428.

35. Baell, J. B.; Holloway, G. A., New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *J Med Chem* **2010**, *53* (7), 2719-2740.

36. Schrecengost, R. S.; Green, C. L.; Zhuang, Y.; Keller, S. N.; Smith, R. A.; Maines, L. W.; Smith, C. D., *In vitro* and *in vivo* antitumor and anti-inflammatory capabilities of the novel GSK3 and CDK9 inhibitor ABC1183. *J Pharmacol Exp Ther* **2018**, *365* (1), 107-116.

37. Koehler, D.; Shah, Z. A.; Williams, F. E., The GSK3 beta inhibitor, TDZD-8, rescues cognition in a zebrafish model of okadaic acid-induced Alzheimer's disease. *Neurochem Int* **2019**, *122*, 31-37.

38. Lovestone, S.; Boada, M.; Dubois, B.; Hull, M.; Rinne, J. O.; Huppertz, H. J.;
Calero, M.; Andres, M. V.; Gomez-Carrillo, B.; Leon, T.; del Ser, T.; Investigators, A., A
Phase II trial of tideglusib in Alzheimer's disease. *J Alzheimers Dis* 2015, 45 (1), 75-88.
39. Metin-Armagan, D.; Gezen-Ak, D.; Dursun, E.; Atasoy, I. L.; Karabay, A.;

Yilmazer, S.; Ozturk, M., Okadaic acid-induced tau hyperphosphorylation and the downregulation of Pin1 expression in primary cortical neurons. *J Chem Neuroanat* **2018**, *92*, 41-47.

40. Wu, X. L.; Kosaraju, J.; Tam, K. Y., SLM, a novel carbazole-based fluorophore attenuates okadaic acid-induced tau hyperphosphorylation via down-regulating GSK-3 beta activity in SH-SY5Y cells. *Eur J Pharm Sci* **2017**, *110*, 101-108.

41. Rankin, C. A.; Sun, Q.; Gamblin, T. C., Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. *Mol Neurodegener* **2007**, *2*, 12.

42. Song, J. S.; Yang, S. D., Tau protein kinase I/GSK-3 beta/kinase FA in heparin phosphorylates tau on Ser199, Thr231, Ser235, Ser262, Ser369, and Ser400 sites phosphorylated in Alzheimer disease brain. *J Protein Chem* **1995**, *14* (2), 95-105.

43. Singh, T. J.; Haque, N.; Grundke-Iqbal, I.; Iqbal, K., Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3. *FEBS Lett* **1995**, *358* (3), 267-72.

44. Garrido, J. J.; Simon, D.; Varea, O.; Wandosell, F., GSK3 alpha and GSK3 beta are necessary for axon formation. *FEBS Lett* **2007**, *581* (8), 1579-86.

45. Medina, M.; Garrido, J. J.; Wandosell, F. G., Modulation of GSK-3 as a therapeutic strategy on tau pathologies. *Front Mol Neurosci* **2011**, *4*, 24.

46. Norman, R. A.; Toader, D.; Ferguson, A. D., Structural approaches to obtain kinase selectivity. *Trends Pharmacol Sci* **2012**, *33* (5), 273-278.

47. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J., Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. *Nat Struct Biol* **2002**, *9* (4), 268-272.

48. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D., Molecular properties that influence the oral bioavailability of drug candidates. *J Med Chem* **2002**, *45* (12), 2615-2623.

49. Zhang, H. C.; Bonaga, L. V. R.; Ye, H.; Derian, C. K.; Damiano, B. P.; Maryanoff, B. E., Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3. *Bioorg Med Chem Lett* **2007**, *17* (10), 2863-2868.

50. Fu, G.; Sivaprakasam, P.; Dale, O. R.; Manly, S. P.; Cutler, S. J.; Doerksen, R. J., Pharmacophore modeling, ensemble docking, virtual screening, and biological evaluation on glycogen synthase kinase-3beta. *Mol Inform* **2014**, *33* (9), 610-26.

51. Sondergaard, C. R.; Olsson, M. H. M.; Rostkowski, M.; Jensen, J. H., Improved treatment of ligands and coupling effects in empirical calculation and rationalization of pK(a) values. *Journal of Chemical Theory and Computation* **2011**, *7* (7), 2284-2295.

52. Harder, E.; Damm, W.; Maple, J.; Wu, C. J.; Reboul, M.; Xiang, J. Y.; Wang, L. L.; Lupyan, D.; Dahlgren, M. K.; Knight, J. L.; Kaus, J. W.; Cerutti, D. S.; Krilov, G.; Jorgensen, W. L.; Abel, R.; Friesner, R. A., OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. *Journal of Chemical Theory and Computation* **2016**, *12* (1), 281-296.

53. Li, J. N.; Abel, R.; Zhu, K.; Cao, Y. X.; Zhao, S. W.; Friesner, R. A., The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling. *Proteins* **2011**, *79* (10), 2794-2812.

54. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G., A smooth particle mesh Ewald method. *J Chem Phys* **1995**, *103* (19), 8577-8593.

55. Martyna, G. J.; Klein, M. L.; Tuckerman, M., Nose-Hoover chains - the canonical ensemble via continuous dynamics. *J Chem Phys* **1992**, *97* (4), 2635-2643.

56. Martyna, G. J.; Tobias, D. J.; Klein, M. L., Constant-pressure molecular-dynamics algorithms. *J Chem Phys* **1994**, *101* (5), 4177-4189.

57. Hayes, J. M.; Skamnaki, V. T.; Archontis, G.; Lamprakis, C.; Sarrou, J.; Bischler, N.; Skaltsounis, A. L.; Zographos, S. E.; Oikonomakos, N. G., Kinetics, *in silico* docking, molecular dynamics, and MM-GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP-binding site inhibitors: The role of water molecules examined. *Proteins* **2011**, *79* (3), 703-719.

58. Baki, A.; Bielik, A.; Molnar, L.; Szendrei, G.; Keseru, G. M., A high throughput luminescent assay for glycogen synthase kinase-3 beta inhibitors. *Assay Drug Dev Techn* **2007**, *5* (1), 75-83.